Company Overview - COMPASS Pathways plc (NASDAQ:CMPS) is a London-based biotechnology company founded in 2020, focusing on mental health and committed to mental well-being [5]. Investment Potential - COMPASS Pathways is considered one of the best stocks for quick wealth accumulation, with a majority of analysts giving it a 'Buy' or equivalent rating. The median price target is $15, indicating an upside potential of 119.14% from the current price [1]. - Oppenheimer upgraded COMPASS Pathways to 'Outperform' from 'Perform', setting a price target of $15, driven by the potential of its psilocybin therapy for treatment-resistant depression [3]. - Gavin Clark-Gartner from Evercore ISI reaffirmed a 'Hold' rating with a price target of $8, reflecting a 16.87% upside potential from the current level [2]. Market Opportunity - Oppenheimer estimates a record sales opportunity of nearly $1.5 billion for COMPASS Pathways' psilocybin-based therapy, COMP360, which is significant compared to the company's current market capitalization of over $600 million [4]. - The company is expected to benefit from an early-mover advantage in the psychedelics space, supported by a strong financial position and adequate cash runway [4].

As filed with the Securities and Exchange Commission on December 5, 2025. Registration No. 333-291817 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLEARMIND MEDICINE INC. (Exact name of registrant as specified in its charter) | British Columbia | 2834 | Not Applicable | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organiz ...

Core Viewpoint - Psyence BioMed is positioned as the only publicly listed psychedelics company with active operations and manufacturing capabilities in Africa, enhancing its access to ibogaine, a compound derived from the Tabernanthe iboga shrub, which is crucial for developing therapies for mental health needs [1][2]. Company Overview - Psyence BioMed focuses on nature-derived psilocybin and ibogaine therapies to address unmet mental health needs, particularly in palliative care [10]. - The company has established a strategic investment in PsyLabs, which operates a GMP-compliant facility in Southern Africa, producing highly purified psychedelic compounds [3][9]. Strategic Positioning - By operating at the source of ibogaine, Psyence BioMed can ensure sustainable and responsible access to this compound, allowing for quality control from cultivation to finished product [2][3]. - The vertical integration of Psyence BioMed's operations strengthens supply security and scalability, positioning the company favorably within the psychedelics sector [3][8]. Market Trends - There is a global surge in interest and research surrounding ibogaine as a potential treatment for addiction and mental health disorders, with significant findings indicating its effectiveness in reducing PTSD symptoms among veterans [4][5]. - The State of Texas has allocated $50 million for clinical research on ibogaine, aiming to develop FDA-approved treatments for opioid use disorder, which reflects growing governmental support for psychedelic medicine [5]. Industry Developments - Major pharmaceutical companies, such as AbbVie, are increasingly investing in psychedelic compounds, highlighting the clinical potential of ibogaine and its analogs [6][7]. - Psyence BioMed is actively engaged in developing next-generation analogs of ibogaine, aligning with the industry's shift towards innovative therapeutic solutions [6][8]. Supply Chain and Compliance - PsyLabs is federally licensed to cultivate and export various psychedelic compounds, ensuring compliance with safety and traceability standards [9][10]. - The company's operations are supported by an ISO 22000-certified facility, emphasizing its commitment to high safety standards and regulatory compliance [10].